Post-hoc analysis for visit-wise differences in dual-task learning. Significant differences between visits are indicated with an asterisk (*). by Swati M. Surkar (8399427)

Number and percentage of AE patients with detectable Em2+ antibodies at different visits and significance level in binominal test. by Beate Grüner (301524)

Distribution of continuous variables of all 3 visits of group 1 (placebo) and group 2 (placebo) that have no significant difference among the groups. by Nattapon Riengvirodkij (11268720)

Subjects:

Time table of follow-up visits of AE patients. by Beate Grüner (301524)

Geographic differences for how the per capita visits to liquor stores changed in response to COVID-19. by Yingjie Hu (1579000)

Subjects:

Distribution of quality of life and respiratory variables scores of all 3 visits (visit = day 0, visit 2 = day 35, and visit 3 = day 70) of the PCSO-524 group and the placebo group... by Nattapon Riengvirodkij (11268720)

Subjects:

A flow diagram outlining the number of dogs in each group during the study (visit 1 = day 0, visit 2 = day 35, and visit 3 = day 70). by Nattapon Riengvirodkij (11268720)

Subjects:

Geographic differences for how the per capita sales of spirits changed during the pandemic. by Yingjie Hu (1579000)

Subjects:

Geographic differences for how the per capita sales of beer changed during the pandemic. by Yingjie Hu (1579000)

Subjects:

Geographic differences for how the per capita sales of wine changed during the pandemic. by Yingjie Hu (1579000)

Subjects:

Multivariable logistic regression analysis of the relationship of the date of a PHC visit with new visits, types of health events, procedure, and outcome of visits. by Taizo Sakata (21567847)

Subjects:

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Dynamics of cortisol levels measured in pregnant women during pregnancy determined at different ANC visits. by Francois Kiemde (5369657)

Subjects:

Distribution of continuous variables of all 3 visits (visit 1 = day 0, visit 2 = day 35, and visit 3 = day 70) of the PCSO-524 group and the placebo group. Results are shown as mea... by Nattapon Riengvirodkij (11268720)

Subjects:

Difference in ED visits in all participating hospitals in 2020 compared to 2019 in percent per hospital per month. by F. Marlijn Booij-Tromp (18592092)

Subjects:

Differences between the endpoints at baseline and 3 months post-enrollment. by Makoto Shimoyama (17290996)

Subjects:

Differences between the primary endpoints at baseline and 3 months post-enrollment. by Makoto Shimoyama (17290996)

Subjects:

Level of IgG IHA over time and difference of respective levels compared to baseline. by Beate Grüner (301524)

General characteristics of self-harm patients who visited emergency departments in the early pandemic (2020). by Ye Ji Lee (11055903)

Subjects:

Initial post-switch visits and SABA prescriptions in each period. by Rieko Kondo (10010647)

Subjects: